GBIO
Price
$0.38
Change
+$0.03 (+8.57%)
Updated
Jul 9 closing price
Capitalization
25.37M
27 days until earnings call
PBM
Price
$4.90
Change
-$0.25 (-4.85%)
Updated
Jul 9 closing price
Capitalization
3.49M
Interact to see
Advertisement

GBIO vs PBM

Header iconGBIO vs PBM Comparison
Open Charts GBIO vs PBMBanner chart's image
Generation Bio
Price$0.38
Change+$0.03 (+8.57%)
Volume$1.08M
Capitalization25.37M
Psyence Biomedical
Price$4.90
Change-$0.25 (-4.85%)
Volume$17.14K
Capitalization3.49M
GBIO vs PBM Comparison Chart in %
Loading...
GBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GBIO vs. PBM commentary
Jul 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GBIO is a StrongBuy and PBM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 10, 2025
Stock price -- (GBIO: $0.38 vs. PBM: $4.90)
Brand notoriety: GBIO and PBM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GBIO: 127% vs. PBM: 10%
Market capitalization -- GBIO: $25.37M vs. PBM: $3.49M
GBIO [@Biotechnology] is valued at $25.37M. PBM’s [@Biotechnology] market capitalization is $3.49M. The market cap for tickers in the [@Biotechnology] industry ranges from $314.48B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GBIO’s FA Score shows that 0 FA rating(s) are green whilePBM’s FA Score has 1 green FA rating(s).

  • GBIO’s FA Score: 0 green, 5 red.
  • PBM’s FA Score: 1 green, 4 red.
According to our system of comparison, PBM is a better buy in the long-term than GBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GBIO’s TA Score shows that 6 TA indicator(s) are bullish while PBM’s TA Score has 2 bullish TA indicator(s).

  • GBIO’s TA Score: 6 bullish, 3 bearish.
  • PBM’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, GBIO is a better buy in the short-term than PBM.

Price Growth

GBIO (@Biotechnology) experienced а +11.99% price change this week, while PBM (@Biotechnology) price change was -13.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.89%. For the same industry, the average monthly price growth was +16.25%, and the average quarterly price growth was +20.89%.

Reported Earning Dates

GBIO is expected to report earnings on Nov 05, 2025.

PBM is expected to report earnings on Jun 25, 2025.

Industries' Descriptions

@Biotechnology (+9.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GBIO($25.4M) has a higher market cap than PBM($3.5M). GBIO YTD gains are higher at: -64.302 vs. PBM (-70.862). PBM has higher annual earnings (EBITDA): -46.56M vs. GBIO (-69.2M). GBIO has more cash in the bank: 158M vs. PBM (1.93M). PBM has less debt than GBIO: PBM (2.5M) vs GBIO (87.6M). GBIO has higher revenues than PBM: GBIO (24.6M) vs PBM (0).
GBIOPBMGBIO / PBM
Capitalization25.4M3.5M727%
EBITDA-69.2M-46.56M149%
Gain YTD-64.302-70.86291%
P/E RatioN/A0.12-
Revenue24.6M0-
Total Cash158M1.93M8,174%
Total Debt87.6M2.5M3,503%
TECHNICAL ANALYSIS
Technical Analysis
GBIOPBM
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
62%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 9 days ago
87%
Declines
ODDS (%)
Bearish Trend 14 days ago
89%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
GBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RCUS9.330.83
+9.76%
Arcus Biosciences
LEN115.364.94
+4.47%
Lennar Corp
TXMD1.220.04
+3.39%
TherapeuticsMD
ADMA18.340.53
+2.98%
ADMA Biologics
STXS2.210.02
+0.91%
Stereotaxis

GBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, GBIO has been loosely correlated with CCCC. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if GBIO jumps, then CCCC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GBIO
1D Price
Change %
GBIO100%
+7.23%
CCCC - GBIO
51%
Loosely correlated
+18.13%
IDYA - GBIO
50%
Loosely correlated
+7.09%
ABOS - GBIO
49%
Loosely correlated
+3.31%
ATXS - GBIO
48%
Loosely correlated
+5.62%
IPSC - GBIO
48%
Loosely correlated
+11.24%
More

PBM and

Correlation & Price change

A.I.dvisor tells us that PBM and ATHA have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PBM and ATHA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBM
1D Price
Change %
PBM100%
-4.85%
ATHA - PBM
30%
Poorly correlated
+9.32%
SLRX - PBM
29%
Poorly correlated
-4.29%
CRBU - PBM
27%
Poorly correlated
+9.37%
VKTX - PBM
25%
Poorly correlated
+0.70%
GBIO - PBM
25%
Poorly correlated
+7.23%
More